SEAGEN INC. Inactive Instrument
Funds and ETFs Seagen Inc.
Equities
SGEN
US81181C1045
Biotechnology & Medical Research
ETFs positioned on Seagen Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.07% | 0 M€ | +4.60% | - | |
| 0.05% | 1,166 M€ | +0.26% | ||
| 0.05% | 607 M€ | +0.05% | ||
| 0.05% | 0 M€ | +4.20% | - | |
| 0.05% | 0 M€ | +18.92% | ||
| 0.05% | 205 M€ | -.--% | ||
| 0.05% | 786 M€ | -.--% | ||
| 0.05% | 23 M€ | -.--% | - | |
| 0.05% | 0 M€ | +12.13% | - | |
| 0.05% | 206 M€ | -.--% | ||
| 0.05% | 284 M€ | -.--% | ||
| 0.04% | 26 M€ | +16.85% | - | |
| 0.04% | 0 M€ | 0.00% | - | |
| 0.03% | 15 M€ | -1.62% | - | |
| 0.03% | 0 M€ | +3.63% | - | |
| 0.03% | 414 M€ | +11.90% | - | |
| 0.03% | 1,006 M€ | -.--% | ||
| 0.03% | 0 M€ | +8.24% | - | |
| 0.02% | 0 M€ | +8.70% | - | |
| 0.02% | 7 M€ | +0.11% | - | |
| 0.02% | 0 M€ | +0.34% | - | |
| 0.02% | 0 M€ | +5.79% | - | |
| 0.02% | 0 M€ | +5.63% | - | |
| 0.02% | 322 M€ | +13.88% | ||
| 0.02% | 29 M€ | -.--% | - | |
| 0.02% | 2 M€ | +3.16% | - | |
| 0.02% | 6 M€ | +3.89% | ||
| 0.02% | 0 M€ | +2.80% | - | |
| 0.01% | 0 M€ | +3.50% | - | |
| 0.01% | 0 M€ | +8.99% |
Seagen Inc. est spécialisé dans le développement et la commercialisation de thérapies à base d'anticorps monoclonaux destinées au traitement du cancer. Le CA par source de revenus se répartit comme suit :
- ventes de produits (87%) ;
- royalties (8,4%) ;
- revenus issus d'accords de collaboration et de licence (4,6%).
Calendar
24/07/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
